Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Excellent Q1 Medipharm :) To bad market doesn't see it !
View:
Post by 1hot-techwoman on May 16, 2024 7:13am

Excellent Q1 Medipharm :) To bad market doesn't see it !

I guess we wait now...no other choice unless you want to give your shares away for nothing......GLTA


TORONTO, May 15, 2024

Completes Major Steps Towards Profitability with Best Revenue and Adjusted EBITDA in Over Three Years

TORONTO, May 15, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids announced its financial results for the three months ended March 31, 2024.

Select Highlights
 -- Revenue increased 67% to $9.8M during the three months ended March 31, 2024 ("Q1 2024") versus revenue for the same quarter in 2023 ("Q1 2023") of $5.8M. -- Q1 2024 gross profit was $2.7M or 27% which improved significantly versus Q1 2023 gross profit of 6.6% and versus the three months ended December 31, 2023 ("Q4 2023") of 24.3% -- Adjusted EBITDA(1) improved 70% to negative $0.9M in Q1 2024 from negative $3.1M in Q1 2023 and improved sequentially from negative $1.6M in Q4 2023. -- MediPharm anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA(2) by a further $1M to $2M, which plans include the ongoing optimization of production and logistics facilities. -- Strong balance sheet with $17M million of cash, and less than $3 million of debt as of March 31, 2023
Comment by Romulus22 on May 16, 2024 8:34am
With all due respect, how will the market 'see it' when the company barely gets the word out? This isn't the market as much as the leadership, their CC's are awful, they share very little, and so on. Many of us investors see it but it is like a well kept secret.
Comment by QContinuum1 on May 16, 2024 8:59am
This isn't about 'getting the word out', they issue their releases for the masses but the real money doesn't wait for the releases. The Q1 numbers were good, but not great.  Pidduck and Hunter are the real deals and have done what was needed to put this business on solid footing.  I'm not sure Strachan is up for the role he's in and personally I think the ...more  
Comment by subaru1 on May 16, 2024 10:06am
Strachan, has to go, he is certainly part of the decline of the company. It seems to me that the top management of that company are too lazy, we don't feel any enthousiasm about the future, CC blablabla on everything that we already know and absolutly nothing to thease the market. It likes they are just waiting. put on some target and we will find out if you can meet them or beat them, with no ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities